Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

July 30, 2024

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 64 min

Earnings Call Speaker Segments

Cecilia Furlong

executive
#1

Operator, thank you, and I want to express my gratitude to all of you for joining us as we review Penumbra's Q2 2024 earnings release. The press release, together with the financial tables — which include a GAAP-to-non-GAAP reconciliation — is available on our website, www.penumbrainc.com, beneath the Investors tab. During this call, we will be providing forward-looking statements in accordance with the safe harbor protections established by the Private Securities Litigation Reform Act of 1995, and these statements address matters such as our financial results, commercialization efforts, clinical trials, regulatory standing, quality, compliance and business trends. Since there are risks and unknowns — including the ones we point to in our 10-K covering the year that closed December 31, 2023, which we submitted to the SEC — what actually happens could end up substantially different from anything those forward-looking statements say or suggest. That's why we strongly advise against leaning too heavily on them, and we ask that you review the filings we make with the SEC on a periodic basis, that 10-K included, to get a more complete picture of these factors along with other risks capable of impacting either our results down the road or the market value of our shares. Penumbra accepts no obligation to update or revise any forward-looking statements, whether due to fresh information, later events, new developments or anything else. During this call, we'll report revenue using GAAP, but for gross margin, operating expenses, operating income, and adjusted EBITDA, we're using non-GAAP figures. You can find the comparable GAAP numbers and a full reconciliation between GAAP and non-GAAP in the press release we've posted. Our non-GAAP gross margin, operating expenses, and operating income leave out amortization tied to acquired intangible assets for both the second quarter of 2024 and 2023, as well as an impairment charge related to our immersive health care business in the second quarter of 2024. Adjusted EBITDA does not include impairment expenses, stock compensation expense, depreciation and amortization, benefit from income taxes, or interest income expenses. Penumbra's Chairman and CEO, Adam Elsesser, is going to share a business update. Next up, Maggie Yuen — she's our Chief Financial Officer — will go over how we performed financially during 2024's second quarter. After that, Jason Mills, who serves as Executive Vice President of Strategy, will walk through the revised outlook we have for 2024. So with that said, let's hand things over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Cecilia. Good afternoon, everyone, and thank you for being with us on Penumbra's call for the second quarter of 2024. For Q2, total revenue came in at $299.4 million, which represents growth of 14.5% versus a year ago as reported, or 14.7% when measured on a constant currency basis. U.S. thrombectomy revenue rose 25% from the same quarter last year, reaching $153.7 million, and in the first half of 2024 it was up 29.8% year-over-year, with our CAVT products in VTE and Arterial driving that. Internationally, thrombectomy revenue totaled $49.8 million, up 26% year-over-year; worldwide, thrombectomy revenue reached $203.5 million, which is 25% higher than a year ago. Global embolization and access revenue came to $95.9 million, down slightly from a year ago, though it was up 5% sequentially, helped by our U.S. business, which rose 9% sequentially and 1% year-over-year to $64.5 million; that strong sequential growth in the U.S. reflected how our sales team responded to the competitive launches seen in the first quarter. Non-GAAP gross margins widened to 65.5%, an increase of 170 basis points from a year earlier. Non-GAAP operating income for Q2 was $31.7 million, or 10.6% of revenue, which is 280 basis points higher than the same period last year and a sequential improvement of 370 basis points. We believe we can reach gross margins of more than 70% in the coming 21 to 27 months, and for the foreseeable future, we expect operating margin growth to outpace gross margin growth. Clot burden that is clinically significant in the arteries, veins, and brain of the body is still one of the most undertreated acute issues in health care today; for over 20 years, Penumbra has kept innovating our thrombectomy products so they can remove clot in the safest, fastest, and simplest way possible. With CAVT's launch last year, we can now say that, when it comes to removing blood clots, our products are the safest and most effective compared with other mechanical systems and other modalities. Because of this, Penumbra is changing — no longer just a business that created new products and cared for patients who could be helped, but one that now carries real accountability to serve most of the 125 million people in the United States who need thrombectomy each year, a task spanning more than the next 5 years. Meanwhile, we've spent several years working toward a comparable, one-of-a-kind opening in our markets abroad, driven by what we've done around reimbursement, clinical ovens, and commercial growth; let's now shift to reviewing the actual results from the second quarter and our outlook for the quarters ahead. We'll start with our vascular business. Our first available Flash 2.0 units arrived in late April, later than we had hoped, but the early cases demonstrated it was worth the wait. Among experienced users of Flash 1.0, the response to Flash 2.0 has been favorable, though more in the sense that it is a very solid iterative product. For those trying Flash for the first time, Flash 2.0 produced an extremely positive reaction. The response starts off with people feeling really positive, saying the procedures moved along far faster than what they're used to seeing now, and the safety picture looked a lot better. There was much less worry about cardiac decompensation, which they credited to the smaller catheter that was used. Nobody had to deal with returning blood that could be compromised, and the blood loss was clinically very acceptable. Another plus was that it stayed inside our pump canister instead of spilling out into the room. This feedback, particularly the part about giving back potentially compromised blood, came up front and center at our recent San Diego VTE Summit, where we pointed to data from extensive testing, the expanding body of evidence, and guidelines that already exist. Doctors are starting to learn about this problem, and as you'd expect, it will probably come up at medical conferences in the near future, where specialists will keep teaching about the documented dangers of putting blood back into the body when it may not be safe. Based on what we're hearing about Flash 2.0, we noticed especially aggressive competitive moves during the back half of the quarter in VTE. Let me be clear: competing is nothing new for us, and we're eager to fight for our position, especially since the response to our offerings tells us they're the top choice for patients. Over the course of 17 years going head-to-head with some of med tech's strongest players, we've learned that the best product wins with physicians in the end; this mission matters and it's thrilling. That said, progress requires patience and never unfolds as a smooth, quarter-by-quarter straight line. A comparable pattern played out in the stroke market years back, when penetration there was just as low and growth was running at a similar clip. Penumbra came out on top as the obvious leader, and we're still building on that standing now. Thanks to Flash 2.0, we picked up considerable VTE share during Q2, expanding at a rate inside the guidance range we'd stated, and we anticipate keeping that up through the back half of the year and afterward. Our arterial segment is doing really well too, with Lightning Bolt leading the way in the U.S. Blood clots are being cleared much more easily than with older methods, thanks to what we refer to as modulated aspiration along with Lightning Bolt. During the second quarter, our U.S. arterial business posted year-over-year growth that came in well above the guidance range we had shared. We also recently had the 12-month STRIDE study data published in the Journal of Vascular Surgery. It showed target limb salvage rates at one year reaching 88.5%, which is higher than the rates found in historical literature for CDT and open surgery — those come in as low as 57% and 65%, respectively. This further supports making an endovascular-first approach the standard for removing arterial thrombus, and it's evident in how strongly our arterial business is growing. Now for our neurovascular segment. We delivered a strong quarter once again, with U.S. stroke revenue up 19% compared to the same period last year. Momentum was also solid in our neuro access unit, helped by the introduction of our midway access catheters. At the Society of NeuroInterventional Surgery gathering in Colorado Springs just last week, Dr. David Fiorella, who serves as a lead investigator on the THUNDER study, gave a late-breaking presentation on Thunderbolt in which he walked through multiple case examples showing how easily the device removes clot. With that milestone behind us, we're in a strong position as we aim to complete THUNDER and prepare Thunderbolt for commercialization. On top of that, it's encouraging to hear so many physicians talking about ensuring catheters of the proper size get selected for stroke procedures, so that an artery isn't stretched by one that's too large. Now I'd like to take a few minutes to walk through our broad market access efforts, which in my view matter a great deal both near term and long term as we build out these thrombectomy markets that remain underpenetrated. Across the last 12 months, we've devoted considerable time and energy, internally as well as alongside a terrific group of outside analytical partners, to producing evidence drawn from extensive third-party hospital data sets, all to gain a clearer picture of how CAVT stacks up against other therapies — anticoagulation alone included — on a broad array of measures. That rigor has led us to complete studies in PE and DVT that we believe establish a high benchmark for data quality and independence. As we'd hoped and anticipated, CAVT beats other advanced therapies on a broad array of parameters tied to hospital efficiency and cost, and, most critically, procedural effectiveness and safety. 1.25 million annual thrombectomy patients in the United States.

Adam Elsesser

executive
#3

Thanks to our ongoing, fast-paced innovation efforts, we anticipate that this increasing relative outperformance will show up in the evidence we produce on a continuous basis starting now. We also intend to create comparable, high-quality data sets covering every vascular bed and patient population that CAVT serves. We've lately begun talks regarding the findings from these high-quality studies with certain of the biggest hospital systems in the U.S; and we're supporting those partners in any suitable manner so that CAVT can be offered to a rising number of patients who might gain from getting this technology. We're eager to share these findings with our partners and the broader physician community in the months and years to come; at this point I'd like to provide an update on our immersive health care business. We've built a remarkable lineup of products that have proven to deliver substantial patient benefit. I couldn't be more proud of our incredible immersive health care team. Despite this belief in the long-term value and probable success of our immersive health care platform and technology, our present priority must be assisting as many patients as we can in our interventional business, especially at this pivotal juncture where we think our CAVT technology can serve most patients requiring thrombectomy. As a result, we've started looking into other options for the immersive health care business. Given that choice, we're recording a onetime noncash accounting charge. While we pursue these options, we anticipate lowering our continuing operating expenses, which will further boost our operating margin and cash flow trajectory moving forward. This strategic step lets us devote 100% of our time, energy and resources toward helping as many patients as possible while also raising our company's profitability. I realize many of you have grown to expect that I'll express strong confidence regarding our business's future; yet my confidence rests on what I and our team witness daily in the field. The 3 new CAVT products we plan to introduce within the next 9 months ought to strengthen our solid position as we head into and progress through 2025. We're equally confident about market growth as well as our market share trends in VTE, arterial and stroke within the United States next year. Naturally, possessing the finest products matters greatly. Still, our confidence is further supported by our extensive market access efforts and our robust commercial footprint. We're also not — we additionally won't face the same tough year-over-year growth hurdles in 2025 across key international markets, specifically China and Europe, that we're confronting during 2024 and we anticipate that launching Flash 2.0 and Lightning Bolt 7 in Europe late this year will deliver a more noticeable effect on our international growth next year. With that said, we've historically established revenue guidance consistent with our best judgment of what we can accomplish. Moving forward, our guidance will incorporate a comfortable degree of conservatism. Jason is going to walk through this revised guidance when we wrap up our prepared remarks. At this point, I'd note that we view the outlook for our business as quite strong across the rest of this year; and as we move into 2025, we get the advantage of new product introductions, ongoing market share growth, and the fading away of the temporary headwinds that weighed on 2024. I'll hand things over to Maggie now so she can take us through our financial results for Q2 of 2024.

Maggie Yuen

executive
#4

Adam, thank you. Everyone, good afternoon. I'll walk through our Q2 2024 financial performance today. The revenue numbers I'll cite are GAAP; gross margin, operating expenses, and operating income are non-GAAP. The comparable GAAP figures, plus a reconciliation linking GAAP and non-GAAP financial measures, appear in the press release we issued. Total revenues for the quarter that closed on June 30, 2024, were $299.4 million, which represents a 14.5% increase as reported and a 14.7% increase in constant currency compared with the second quarter of 2023. Sales in the second quarter of 2024 broke down geographically as 72.9% U.S. and 27.1% International. Our U.S. That area saw a 16.8% increase, driven by a 24.9% rise in our thrombectomy franchise. Our markets outside the U.S. gained 8.7% as reported and 9.4% in constant currency, largely due to higher overall thrombectomy revenue, partially offset by a decrease in the embolization and access franchise across multiple regions. Total revenues grew 7.4% sequentially, mostly because of a $15.8 million, or 8.4%, increase in our global thrombectomy revenue. Now looking at revenue by products. In the second quarter of 2024, revenue from the global thrombectomy business reached $203.5 million, rising 25.2% as reported and 25.4% in constant currency compared with the same period last year. Our U.S. We saw 24.9% growth, which came from higher volumes among new accounts added since last year, along with a 26.2% increase internationally compared with the same period a year ago — both pointing to ongoing strong momentum in CAVT products. In the second quarter of 2024, the embolization and access business brought in $95.9 million, down 3.1% as reported and 3% on a constant currency basis, primarily because of a broad decline across international regions, consistent with what we flagged at the start of the year. Our non-GAAP gross margin, operating expenses, and operating income each leave out amortization tied to acquired intangible assets totaling $2.4 million in the second quarter of 2024 and 2023, respectively, as well as a $110.3 million impairment related to our immersive health care business recorded in the second quarter of 2024. When you look at adjusted EBITDA, it leaves out a few things: the $110.3 million in impairment expenses, stock compensation, depreciation and amortization, benefits from income taxes, and interest income expenses totaling $3.8 million. For the second quarter of 2024, gross margin came in at 65.5%, up from 63.8% in the same period of 2023. That 170 basis point gain came from a favorable mix of thrombectomy products across every region, along with productivity gains; looking ahead, we anticipate consistent improvement through the back half of the year and remain on track for gross margin expansion of 100 to 150 basis points in 2024. Operating expense for the quarter totaled $164.5 million, which works out to 54.9% of revenue, versus $146.6 million, or 56.1% of revenue, in last year's comparable quarter. R&D spending in the second quarter of 2024 totaled $24.9 million, up from $21.5 million in the same period of 2023. SG&A for Q2 2024 was $139.6 million, representing 46.6% of revenue, compared with $125.1 million, or 47.8% of revenue, in Q2 2023. Operating income in Q2 2024 came to $31.7 million, or 10.6% of revenue, versus $20.3 million, or 7.8% of revenue, in the prior-year quarter. As Adam noted during his discussion of our immersive health care strategic initiative, we expect to eliminate over $20 million in ongoing operating expenses and unlock more than $20 million in cash over the next 12 months. That should help drive operating margin expansion in 2025. Adjusted EBITDA came to $46.3 million, or 15.5% of total revenue, versus 14.6% in last year's second quarter. Now moving to cash flow and the balance sheet. We closed Q2 with $339.7 million in cash, cash equivalents and marketable securities, along with no debt — a $26.2 million increase, fueled by operational profitability and better working capital turns. Our outlook remains for positive operating cash flow trends through the remainder of 2024. At this point, I'll hand the call to Jason so he can go over our guidance.

Jason Mills

executive
#5

Thanks, Maggie. So, under our revised outlook for 2024, we now expect total revenue between $1.180 billion and $1.200 billion — that's a $60 million decrease at the midpoint versus what we previously told you. Four separate items account for that $60 million shift in guidance, all hitting our revenue in the back half of the year: a $20 million cut to our China business, reflecting a significantly tougher near-term economic environment for medical devices; $15 million tied to our European business, mostly stemming from a minor postponement in the anticipated launch timing for Flash and Bolt 7 CAVT products in Europe; $5 million in revenue from our immersive health care business, driven by our strategic move; and roughly $20 million of change to our U.S. thrombectomy growth guidance for the full year 2024, which we now expect to come in at 23% to 25% year-over-year against 2023. This shift is consistent with our new guidance philosophy. We still anticipate non-GAAP gross margin expansion of 100 to 150 basis points for 2024 versus the full year 2023. We also still expect non-GAAP operating margin expansion of 100 to 200 basis points in 2024, and the timing around reducing immersive health care expenses will be the main factor determining where we finish within that range. That's where I'll end our prepared remarks so we have plenty of time for Q&A. We're eager to hear your questions. Operator, please open the call for questions.

Michael Sarcone

analyst
#6

To kick things off, could you go deeper into the new approach to guidance that you brought up, Jason or Adam? You also said you're adopting a more conservative stance, but I'd appreciate it if you could expand on that for us. And I'm really just wondering about the components that took you from U.S. thrombectomy plus 27% to 30% down to 23% to 25%.

Adam Elsesser

executive
#7

Yes. Michael, thanks for those questions; this is Adam. Look, across the span of virtually 10 years—though not quite—since we became a public company, we've clearly changed significantly from what we used to sell. At the outset, our focus was solely stroke, and we grew the company's size quite substantially during that period. Naturally, then, the moment has come for our approach to guidance to broaden and develop alongside that. Guiding was far simpler when we were a considerably smaller business. There were hardly any moving components. And we did a fairly solid job of guiding according to what we were confident we could deliver. My sense is that we've reached a stage where numerous factors are in play; we've clearly picked up on market discussion regarding this and our guidance practices, and we wanted to introduce somewhat more reassurance into how we provide guidance. Having said that, I'm not claiming guidance is now something like a layup, but each quarter demands considerable effort from us to keep growing the business at the pace we believe is achievable. Still, I view it as a significant recognition, a point in time for us to ensure that this isn't the subject we're constantly discussing. I believe we've sacrificed part of the company's narrative when the bulk of our time goes toward discussing our guidance rather than the remarkable power of the innovation that got us here, with products that have completely reshaped how thrombectomy is performed. That represents the company's story. That's the achievement we hold. That's what lies ahead for us, and the time has come for us to stop devoting so much attention to our company's guidance philosophy and instead focus on innovation and the remarkable path before us through this year, into 2025 and beyond.

Michael Sarcone

analyst
#8

Got it. As for my second question, I thought I would give it a shot. You mentioned a few of the more difficult comparisons that lie ahead for this year. Looking toward 2025, especially in U.S. thrombectomy, could you speak either quantitatively about what we might expect relative to '24 for U.S. thrombectomy growth? Or, if not, qualitatively, what are the main factors driving that path?

Adam Elsesser

executive
#9

Yes. Well, to start, I truly value the question; and I doubt you'd anticipate that I would possibly repeat the error I made in 2024 by giving a quantitative response to that. So, with respect, I'll pass on that. But I will share what we did — what we have ahead of us; and I touched on this briefly during the prepared remarks. Certain aspects of 2025 are somewhat different. To begin with, we no longer face a few of those same transient headwinds we discussed on last quarter's call and repeated on this one regarding the embo and access business and leaving some of those markets that will be — we'll reach the anniversary of that. That will be in the past. There are certain matters with China we've addressed previously on the last call. We pointed them out again with a specific figure this time, and that will sort of be in the past. And then we'll enjoy the advantage of new product launches we've discussed in terms of new products in the U.S., but also in Europe with Flash 2.0 and Lightning Bolt arriving; so there's plenty to anticipate in the back half of this year, but there's also, I believe, plenty to anticipate in 2025; and again, I won't put a number on that, but I can — I hope you can tell that I believe with 2024 and some of the things we're sort of navigating this year, moving beyond 2025 is going to be another really enjoyable year for us.

Phil Dantoin

analyst
#10

Phil Dantoin here, filling in for Matt. To begin with on U.S. thrombectomy, how should we interpret that roughly 20% growth during the back half of the year relative to the broader market? We recognize you're up against some tough comparisons, yet does this reflect more of a broad move toward your conservative guidance approach? And more pointedly, is there anything further you can share regarding added competitive pressures?

Adam Elsesser

executive
#11

Yeah. What we said about our guidance, I believe, was quite straightforward. Looking at what we achieved this quarter, we couldn't be more proud. Let me begin and walk through it. Our stroke business, now fairly mature, nevertheless expanded 19% versus the prior year. So hopefully that's clear to people — that reflects a strong position, and it isn't the situation for the other businesses we go up against — keep in mind there are roughly 30-some-odd catheters in the market that we're competing with. Achieving that is quite meaningful. And the sentiment, the atmosphere, and the morale at the SNIS meeting just last week were — I've attended that meeting, I believe, for 21 years. And I had never witnessed anything like it surrounding our technology and our success. Attending SNIS this year was a lot of fun. So that covers the stroke side; regarding VTE, as I stated, we expanded at the top end of the range we'd previously given. So that falls in the very high 20% range. Clearly, that meant we gained share while the market expanded considerably. That's an excellent position going into the back half of the year, when we'll have complete quarters with Flash 2.0 and truly enter this next phase. And once more, the feedback I described, not just regarding the speed of the cases, which is really the first thing people notice, but also some of the safety and performance matters I pointed out in the prepared remarks. Then there's arterial as well, which expanded far beyond that range; and that's now a year past launch. So that's facing the comparison against the launch quarter, and we still performed really, really well. So I believe we're again positioned for an outstanding remainder of this year and heading into a truly excellent 2025. And perhaps we got a bit ahead of ourselves. It's quite difficult not to when you receive the sort of feedback we get daily from customers. And that falls on me personally, clearly. I accept that responsibility, yet it truly has no bearing on the fundamental success in innovation and performance of our company at present.

Phil Dantoin

analyst
#12

Glad that was useful. Now, one more brief question. Regarding the strong U.S. thrombectomy expansion during Q2, once we begin comping against certain ASP mix advantages, could you assist in breaking down the base procedure counts, what direction did those take this quarter and what you anticipate for the remaining months?

Adam Elsesser

executive
#13

Sure. Within our thrombectomy segment, all base procedure counts have risen, matching the figures I mentioned. As you're aware, we've now cycled past much of the pricing element. So right now, it's — nearly all of it comes purely from volume and units. And obviously, that pattern will persist moving ahead.

Jason Mills

executive
#14

Yeah, Jason here, just to build on what was said. We hear that question frequently when it comes to our VTE business. And in fact, all of the growth we saw this quarter compared with the same period last year came from more cases, meaning higher unit volume.

Lei Huang

analyst
#15

This is Lei, filling in for Larry. Your OUS thrombectomy figures for Q2 exceeded our forecasts, rising more than 25% versus the prior year. Could you explain what was behind that? Did any one-time factors play a role? Also, on that topic, if you could share thoughts on the OUS thrombectomy outlook — I believe you had anticipated mid- to high single-digit expansion for the full year. What does that imply now, considering the Lightning Bolt and Lightning Flash delays, though Q2 performed well? And if you could speak broadly regarding U.S. and OUS embo and access for the remainder of the year, whether your growth expectations have shifted for any of those segments.

Adam Elsesser

executive
#16

Okay. Excellent question. My understanding is that we'll discuss our thrombectomy operation globally along with our embo and access operation globally. So let me do my best with that. Our OUS thrombectomy operation fell roughly within the typical range, perhaps slightly above or below. Nothing stands out as unusual regarding this quarter's results; and looking ahead, we highlighted China as well as Europe. Europe is quite straightforward, just so you're aware, moving forward, which is that we — a minor postponement in regulatory approval for both Lightning Flash 2.0 and Lightning Bolt 7. Nothing regarding that has suggested to us in any way that there's a problem with the approvals, that they're at risk, and we completely anticipate launching them afterward this year, merely without the same timeline to produce that entire expected revenue. So that will, once more, contribute to helping — that revenue isn't gone. Clearly, it will simply contribute more in 2025 and afterward; and in China, that operation, as you're aware, we have 3 revenue sources there. We have licensing. We have royalties and distribution. And we're transitioning as we shift away from licensing our older generation items that are basically designated for local use. We're transitioning; we've secured approval for more of our present flagship items that carry a higher price. And considering the economy and everything else, that won't be as feasible a revenue source in the near term. But everyone we've spoken with, we have a phenomenal distributor, our partner in China. They believe that will probably return at some point next year, and once more, will remain a valuable component of our operation. Just to set a baseline, China represents roughly 2% or so of our operation. It's not a significant amount that would put us in danger. Regarding embo and access, it's truly tied to our exiting specific countries with both of those product categories and working through that this year. And once more, absent that as the comparison, we'll be in excellent position for expansion in those markets. To wrap up on one item from the prior quarter: there was talk about it, and clearly our embolization and access segment landed a bit below what had been anticipated. This time around, we answered the competitive pressures and product introductions. Honestly, I have to say I feel tremendous pride in our team. Having the top product available certainly makes a difference. It also helps to remind doctors that they always prefer to work with the finest product; and my sense is that this business is positioned quite well going forward.

Jason Mills

executive
#17

Right; and Lei, I'll just build slightly on what Adam mentioned, once more reinforcing his points regarding how much stronger the comps look for 2025. He brought up that within China, it's mainly our distribution and royalty streams that get hit by economic conditions. That's the $20 million I highlighted during my prepared remarks, which works out to roughly $10 million each quarter. And when you combine that with the European CAVT launch being pushed back, compared with the second quarter, our OUS thrombectomy will decline sequentially by around $10 million versus Q2, then stay roughly level going into Q4. Once again, as we move into 2025, all of this will work in our favor, but hopefully that provides a bit more context.

Lei Huang

analyst
#18

That's really useful. If I could just slip in one final one. Jason, you brought up the 100 to 200 basis points of operating margin improving year-over-year, and where you end up depends on immersive health. I suppose I'm somewhat surprised the margin guidance doesn't shift based on the immersive health decision. The 100 to 200 basis point improvement was something you discussed earlier in the year. I assume the move in immersive health wasn't included in those numbers initially.

Maggie Yuen

executive
#19

Yes, Lei, this is Maggie. Thanks for asking. There are actually a good number of factors that influence our range of operating margin, particularly with our updated revenue guidance, that will have roughly $30 million of reduced gross profit, and the impact will pull through to the bottom line in the operating profit. But at the same time, I mean, given our first half of the year, we have more than 200 basis point operating margin expansion, so we're already off to a good start; and then so it hinges on the timing of the immersive health care savings in the second half of the year, this will give us a good range between 100 and 200 basis point expansion.

Pito Chickering

analyst
#20

Turning back to the outlook topic regarding U.S. clinical thrombectomy. A 24% expansion rate still suggests fairly sharp quarter-over-quarter growth for U.S. thrombectomy compared with the 2Q figure we observed. What I'm wondering is, what makes you folks confident that you'll reach that quarter-over-quarter growth that's essentially built into the guidance?

Jason Mills

executive
#21

Peter, that 23% to 25% figure for U.S. thrombectomy represents a yearly number. Consequently, the year-over-year growth it suggests for Q3 and Q4, respectively, comes out to roughly the same — approximately 20% growth measured year over year.

Pito Chickering

analyst
#22

Okay, so let me ask about U.S. sequentially, I suppose. It went up by $3 million from one quarter to the next in 2Q. At the midpoint, this 19% growth means $6 million more in the third quarter, and then $9 million more in the fourth quarter — so that's a fairly sharp step-up quarter over quarter. So I suppose what makes you confident you can reach that rate of growth?

Adam Elsesser

executive
#23

Yeah. Adam here. In our prepared remarks, we described how the first of our new products, Flash 2.0, is performing and what we're observing there. So at this point we aren't merely speculating. We've had more than half a quarter, 6 weeks plus, to truly get a handle on how it's going. For clear reasons, we didn't assign much revenue to the other new products, since we don't fully have control over the regulatory process. But clearly, that isn't out of the question. One of them is under submission, and it could potentially contribute. Once you total that up and factor in the extent of conversation about the speed of flash, the success with Lightning Bolt on the arterial side, some of the safety issues I raised, I believe the momentum is unmistakably with us. I think you can see that, obviously, today in a wider look at the field and the market — we're the ones steering this now. And I think that's completely clear. And I think the new numbers obviously are — we wouldn't have released them and not believed they were highly achievable.

Pito Chickering

analyst
#24

All right, that's helpful. And now I'd like to ask something related to 2025. I realize you won't be providing guidance, but growth in the third and fourth quarters came down by 10%. You mentioned temporary challenges and China going up against new product introductions. Is it still reasonable to expect a pickup from that 10% rate as we exit the year heading into 2025?

Adam Elsesser

executive
#25

Well, once more, I'll keep using my more qualitative wording rather than adopting the specific terms you introduced or putting numbers on them, for reasons that are clear, and I hope you'll honor that and bear with me. That said, you clearly grasped what 2025 will resemble based on how I described it qualitatively.

K. Gong

analyst
#26

Allen here, filling in for Robbie. There's one thing I wanted to ask, plus a brief follow-up. I really don't want to dwell on this, but when we look at the back half guide — to put your updated guidance in other words — it seems like you're pointing toward a range you believe ought to be cautious and ought to be reachable. So as we consider how you might arrive at, say, the guidance range you gave before, if we're talking about possibly exceeding it, what actually gets you there? And is there any market dynamic you'd point to that caused you to choose a somewhat more cautious path with the guide this quarter?

Adam Elsesser

executive
#27

Yes. That's a very good question. Nothing in the market is new or surprising; and I think if you look at our — if you simply concentrate, say, on VTE, nobody else did as well as we did; our performance this quarter was really strong. Clearly, arterial has a somewhat different dynamic; we aren't truly competing with other companies and products, but rather with decades of tradition around treatment; and then stroke kept performing well in a crowded field. Those are the favorable dynamics that have unfolded now and, we believe, truly will keep unfolding through the quarter. What I mentioned before is, because of how successful we are, because of how strong our innovation is, because of the ongoing innovation still to come, it simply appeared to make no sense for us to devote all our time to discussing our guidance and defending our guidance, let's just devote our time to performing and delivering the sort of numbers we just described. So that, more than anything, is really the point. And I know, more than anything, that all of you appreciate that and respect it. So now we get to work; and that's when we're at our best — when we're out in the field doing the work, discussing how successful the products are, the safety aspect of the products, and those conversations matter more right now than they ever have.

K. Gong

analyst
#28

Understood. And a quick second question — again, perhaps to touch on where there might be some upside — how are we supposed to view you, given that you mentioned certain competitive moves that came up during the quarter tied to the new launch? Compared with what we had modeled, U.S. thrombectomy appears to still show solid growth versus a year ago, yet it clearly seems to have decelerated somewhat on a sequential basis. So how do we consider the chance that those competitive moves carry on through the second half? And even for the new products you're launching that will contribute in 2025, the possibility of competition at the high end. What's your approach to navigating all of that from here?

Adam Elsesser

executive
#29

Right. Let me be clear. Whenever we discuss competitive moves, the truth is we have always faced competition. And clearly, all of you have followed us from the time of our IPO, and we've gone up against some of the largest and strongest players in med tech. And within stroke, we came out, clearly, in a fairly strong position. So this wasn't — none of this came as a shock. The one piece that perhaps did come as a shock was the tactics used given the situation. I'd say — we were somewhat taken aback by a few of those tactics, and I'm not certain they were logical. But fine, that's nothing new for us. Another element that shifted, on the flip side, is the degree of interest, the degree of discussion among physicians, discussions that physicians themselves are starting, not us. We aren't the ones raising the safety topics, especially regarding cardiac decompensation, especially regarding introducing compromised blood. Those discussions are taking place with physicians everywhere. And I believe that's wonderful, since it's knowledge we already had, yet it wasn't really for us to bring up other companies' products, and now it's physicians doing so, not us. And I think over the long term that's excellent for the field, because clearly the field has to expand, and expansion only happens when safe products are being used; so I believe that leaves us, within the field, in a truly strong position as we move ahead.

Richard Newitter

analyst
#30

Thanks. Perhaps at the outset, regarding the U.S. thrombectomy segment, I'm simply reviewing the pieces we've modeled. Clearly, venous is expanding quicker within U.S. thrombectomy compared to neuro. Yet neuro is genuinely delivering strong results during the first half, 27% in 1Q, 19% in 2Q. Those figures exceed our expectations. So I suppose what I'm asking is whether we ought to view the U.S. thrombectomy components as being somewhat more heavily propelled than your initial assumptions entering the year, with an upward revision for U.S. neuro thrombectomy, and that perhaps — returning to the earlier point about sequential growth — this shifts the sequential growth trajectory somewhat toward the back half, letting venous potentially ease a bit, while you can still reach that robust 23% to 25%?

Adam Elsesser

executive
#31

Yeah. Providing you with responses to that sort of granular modeling inquiry isn't possible for me at this moment. What I can offer qualitatively, or, once more, sort of walking through it: the momentum behind Flash 2.0 in VTE is excellent. I don't anticipate that momentum fading. That's simply a qualitative response. The achievement of our arterial franchise, featuring Lightning Bolt — clearly, you've now observed the figures. It has performed remarkably well. I lack the precise figure, yet my belief is we've surpassed 20,000 cases utilizing Lightning Bolt 7 technology, which, incidentally, represents very comparable technology, nearly indistinguishable from what we're deploying with Thunderbolt, so it signals very positively for Thunderbolt's arrival, clearly. But addressing specifically neuro's success, we possess — we take considerable pride in our products. We've performed quite admirably. I referenced the sentiment at SNIS. There was, once more, a period of a year or 2 when we faced countless competitors and everybody was introducing 30-some-odd catheters, all those large catheters, this and that. And I believe that era has now concluded. Individuals are returning to the superior products. They've experimented, they understand what performs best; and I believe that positions us once more for genuine success moving forward; and afterward the preparation for Thunderbolt is precisely what I'd hoped for, namely that as increasingly more individuals use our catheter, launching Thunderbolt becomes simpler since Thunderbolt merely constitutes an add-on. Convincing anyone to change catheters isn't necessary; so once more, I cannot completely foresee precisely what lies ahead, but I favor our odds. The preparation is truly favorable for us.

Jason Mills

executive
#32

Rich, I'll tack on one more point here too. So what our revised guidance implies is a direction — we don't provide guidance broken out by U.S. thrombectomy category, but to give you a qualitative sense, it follows a comparable pattern to what showed up during the first six months of the year: VTE along with arterial should expand beyond that range, stroke roughly in line with it, and coronary probably in the double digits, though on the lower end of double digits.

Richard Newitter

analyst
#33

All right. Then, regarding those questions about competition in venous that you addressed — I want to get a clearer picture of what the market's underlying growth rate actually is, plus roughly where you sit compared to it. Was it simply that you picked up slightly less share? I realize it will never move in a straight line; and during these first few weeks of 3Q, do you feel confident that you're once more on the same share-gaining path you had before? What message ought we to draw concerning rivalry, the market's underlying expansion, and approximately where you stood versus where you're headed?

Adam Elsesser

executive
#34

Well, look, I mean, clearly during Q1 the market expanded nicely and was in good health, and on top of that we gained share. We are — I'm somewhat handicapped here since our VTE competitor happens to be holding their call at the very same moment; therefore I'm unable to give you every detail of their figure right now, yet based on the headline I apparently received just before joining this call, we — once more, the market expanded, and we gained share. So provided both of those items are occurring, the first being essential — that the market keeps expanding — and the second being just as essential — that we keep gaining share, now across 2 quarters consecutively, we're about to have a few complete quarters of Lightning Flash 2.0. My sense is this genuinely positions us once again for a truly solid, ongoing share improvement together with market expansion.

Zachary Day

analyst
#35

Zachary here, filling in for Bill. I'd like to dig a bit deeper into how coronary is doing. I realize you only covered it quickly a moment ago. Could you share any extra specifics regarding that growth? And do you figure another study will be necessary to get it moving?

Adam Elsesser

executive
#36

Yeah. Fair question — and, honestly, we haven't devoted much airtime to the coronary area. If you'll recall, CAVT isn't something we offer there. And as I believe you know, the study we actually conducted demonstrated a case time of about 1 minute while the device was inside the body. It's tough to beat that speed. So the device is already performing. Coronary clots are largely a different situation. A few exceptions exist, plus a limited subset of cases where extraction proves somewhat trickier and a CAVT offering might help, yet that's a comparatively modest count. So essentially, what you're seeing is steady momentum toward our device, since it clearly performs extremely well, though it's simply a separate beast. What you're really asking is whether outcomes would improve, whether our share would grow, if we were to run something like a randomized study capable of influencing guidelines. That's something we've examined. A few years back we discussed it, and I believe you recall that. On the cost-versus-benefit question for that product — once more, it doesn't rely on CAVT, lacks dedicated reimbursement, and is essentially folded into procedural reimbursement — we concluded it didn't make sense to pursue. Still, we keep revisiting that matter; should circumstances shift, or should some factors behind that choice change, we might reach a different conclusion. As things stand, though, when you consider the good we can deliver to patients, that good lies in the vascular beds, VTE, PE, arterial and stroke, where CAVT sits at the center. Reimbursement there is distinct and standalone. That, I believe, is where our greatest impact lies. So near term, that's where we'll concentrate; nonetheless, CAT RX, our coronary offering, remains a remarkable device; among those who use it, it stays tied as one of the most sticky products alongside our newer CAVT offerings, more than anything else we've ever made.

Zachary Day

analyst
#37

Great. And as a quick follow-up, can you share anything new regarding the THUNDER study?

Adam Elsesser

executive
#38

Actually, I touched on that somewhat during my prepared remarks. Dr. Fiorella did an excellent job walking through the trial, and the design along with the technology presented a number of cases; so I believe we are — and this has us really enthusiastic. I won't offer much in the way of commentary about timing, clearly, especially regarding the THUNDER study. I've previously made that error too. So I'll stay disciplined here, which is a rather wonderful position to be in — not handing you an update. Yet I think that had you paid attention to what I said, in particular, you'd pick up on how excited I am about this.

Macauley Kilbane

analyst
#39

Macauley here, filling in for Margaret. So, starting with margins. You clearly restated the gross and operating guidance for this year. I'm curious whether you could sort of bridge the path to that 70% gross margin over the longer term, which you placed around the first half of 2026. Given the choice to exit immersive health care, should we view that as happening sooner now, and what might we see in terms of leverage, particularly in that OpEx line you brought up in the prepared remarks?

Maggie Yuen

executive
#40

Thanks for asking; on gross margin, the move regarding immersive health care will barely affect it. Yet over the past few quarters, ever since we launched CAVT, we've witnessed a fairly steady widening of gross margin driven by product mix. So near term, we anticipate that pattern continuing; but I'm also quite glad that our operation team keeps executing and refining their manufacturing process. Thus, over the longer term, I believe it will let us reach a bigger scale cost improvement that gets us to the 70%-plus goal; regarding operating expense, as I said in the remarks — over the next 12 months, we'll realize more than $20 million of savings, operating savings coming from the immersive health care business.

Macauley Kilbane

analyst
#41

Understood. Let me squeeze in one more thing while we're at it. You said the competitive situation isn't really any different, and you've been through comparable circumstances in stroke. So within the thrombectomy competitive landscape in VT broadly, what have you done lately? Does it lean more toward pushing hard with the fresh sales team, or more toward steadily building out the clinical evidence you're expecting to generate?

Adam Elsesser

executive
#42

Yeah, that's a reasonable thing to ask. Clearly, a portion of our efforts I won't reveal during this call, since that would tip off our rivals about our plans; I'm sure you get why that makes sense. Really, it boils down to giving customers room and getting them involved in conversations about the current state of things, what physicians are up to, and what these devices are truly accomplishing. When you approach it that way — and once more, we have done this — the door opens up; people who insisted a year back that they were perfectly satisfied with their current choice are now showing willingness to try Flash 2.0. Their willingness to discuss how much better 2.0 performs by comparison is the most encouraging part; that has enabled us to pursue opportunities across the board rather than splitting things into our accounts versus someone else's accounts. It amounts to having permission; if you went out into the field and spoke with people, you'd find this occurring, and it's occurring in every region — you can even ask former reps. The overall feeling and morale are unmistakably shifting our way. That's because ultimately, look, competing isn't mainly about strategy, which you can always copy. Those moves don't reliably deliver. What matters is fielding the strongest products. Honestly, after more than two decades at this, I've consistently seen that doctors end up choosing whatever product works best. That's the way you win. You offer superior products, and you speak about them confidently while teaching others about them. That approach wins. It has carried us to this point across 20 years, and it's what we'll keep doing from here on.

Cecilia Furlong

executive
#43

Appreciate it, operator. Our management team wants to say thanks once more to everyone for being here with us and for the interest you've shown in Penumbra. We're eager to bring you up to speed on our call for the third quarter.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.